Financial Data and Key Metrics Changes - Total sales grew by 25% year-over-year to $845 million, with 14% organic adjusted sales growth [5][13] - Adjusted operating income increased by 31% to $86.2 million, and adjusted EBITDA rose by 26% to $102.1 million [5][13] - Adjusted diluted EPS was up 26% year-over-year to $1.25 per share [16] Business Line Data and Key Metrics Changes - Parts supply sales grew by 45% to $392.5 million, with new parts distribution growing 62% in total and 36% organically [16][17] - Repair and engineering sales increased by 23% to $265 million, though margins were negatively impacted due to the integration of HAECO Americas [18] - Integrated solutions sales rose by 3% to $167.8 million, driven by Trax and government programs [20] Market Data and Key Metrics Changes - Sales to commercial customers were up 27%, while sales to government customers increased by 19% [13] - Government customers accounted for approximately 30% of total sales, with a 19% increase in government sales this quarter [10][13] Company Strategy and Development Direction - The company is focused on executing key initiatives, including the integration of HAECO Americas and expansion of hangar capacities [6][11] - AAR is positioned as an independent value-added aftermarket solution provider, benefiting from a balanced exposure to both government and commercial markets [9] - The company plans to host an investor day to share its strategic vision and growth plans [23] Management's Comments on Operating Environment and Future Outlook - Management noted strong fundamental demand for air travel, with record bookings despite geopolitical tensions [9][30] - The company expects total adjusted sales growth of 19%-21% for Q4, with organic adjusted sales growth projected between 6% and 8% [22] - Management expressed confidence in maintaining strong operational performance and cash flow generation [50] Other Important Information - The integration of HAECO Americas is progressing ahead of schedule, with expected margin improvements as the integration continues [15][73] - The Trax software platform is experiencing significant growth, with a deployment plan for Delta expected to ramp up user engagement [66] Q&A Session Summary Question: Impact of oil prices and capacity adjustments on business - Management indicated that fundamental demand for air travel remains strong, and modest capacity adjustments are not expected to impact maintenance schedules or parts demand [28][30] Question: Breakdown of organic growth in new parts distribution - Approximately two-thirds of the growth in new parts distribution was from same-store sales, with the remaining third from new contract wins [31][33] Question: Visibility on new parts distribution and repair engineering - Management expressed solid visibility through the quarter and into the summer, with no material changes in demand for maintenance or component repair [40][41] Question: Sources of outperformance in margins - Key contributors to margin outperformance included ADI and HAECO, along with strong performance from the Trax software platform [43] Question: Integration progress of HAECO - The integration is ahead of schedule, with workforce adjustments and operational efficiencies being implemented [72][73] Question: Future growth expectations for Trax - Growth in Trax is expected to be linear, although some lumpiness may occur due to the nature of software implementation [75]

Financial Data and Key Metrics Changes - Research and development revenue for Q4 2025 was $3.8 million, down from $7.6 million in Q4 2024, reflecting a reduction in reimbursed study costs as the company neared completion of the BARDA contract base phase [16] - Gross margin for Q4 2025 was 39.8%, compared to 44.0% in Q4 2024, primarily due to a lower percentage of reimbursed direct labor [16] - Net income for Q4 2025 was $0.6 million or $0.02 per diluted share, compared to a net loss of $7.7 million or -$0.41 per diluted share in Q4 2024 [17] - For the full year 2025, research and development revenue decreased to $19.7 million from $29.6 million, while gross margin remained stable at 45.4% [18] - The net loss for the year was $7.6 million or $(0.29) per diluted share, an improvement from a net loss of $15.3 million or $(0.85) per diluted share in 2024 [19] - Cash position improved to $15.4 million from $5.2 million at the end of 2024, reflecting successful debt and equity financings [19] Business Line Data and Key Metrics Changes - The DeepView system is positioned as a diagnostic tool for burn injuries, with significant advancements made in its development and validation [5][6] - The company completed a 15-month burn validation study involving 164 patients, demonstrating that the DeepView system outperformed clinical judgment [8] - The BARDA contract has been crucial for product development, with a recent $31.7 million funding awarded to accelerate the DeepView system's development [10] Market Data and Key Metrics Changes - Approximately 125 burn centers, 700 trauma centers, and 5,400 federal and community hospitals in the U.S. represent potential markets for the DeepView system [9] - Internationally, positive user feedback has been received from the DeepView systems placed in the UK, with plans for expanded authorization and sales in 2026 [11][12] Company Strategy and Development Direction - The company aims to commercialize the DeepView system, with a focus on preparing for FDA approval and expanding its sales team [5][20] - Plans include a label expansion for the DeepView system and enhancements to its total body surface area measurement tool and EHR integration [30] - The company is also exploring additional indications for the DeepView system beyond burn injuries, such as critical limb ischemia [55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about receiving FDA approval for the DeepView system by the end of Q2 2026, which would enable commercial activities to begin [8] - The company entered 2026 with a strong liquidity position, allowing it to pursue growth objectives effectively [15] - Revenue guidance for 2026 is approximately $18.5 million, which includes the impact of new BARDA funding [20] Other Important Information - The company has engaged Deloitte Consulting to assist with its strategic plan for commercialization [24] - A no-cost extension of the Department of Defense contract has been signed, allowing for further development of a handheld device [13] Q&A Session Summary Question: Preparation for commercialization - The company is searching for a new Chief Commercial Officer and expanding its sales team in preparation for commercialization [24] Question: Impact of BARDA funding on business model - Each health system will determine how to treat the device, impacting revenue recognition, with potential for significant revenue in 2027 and 2028 [26] Question: Use of additional BARDA funding - The funding will support label expansion, improvements to the DeepView system, and economic outcome studies [29][36] Question: Timeline for BARDA funds disbursement - The BARDA contract extends until 2030, with an acceleration of revenue expected through 2028 [42] Question: Training for device implementation - The company plans to expand its training force and sales team to ensure effective training for health systems [50] Question: R&D spend allocation - The company will focus on label expansion and exploring additional indications for the DeepView system [55]

Financial Data and Key Metrics Changes - The company reported total revenues of approximately $1.1 billion and diluted earnings per share of $0.52 for the first quarter of fiscal 2026, reflecting a 23% decrease in housing revenues year-over-year [6][29]. - The housing gross profit margin was 15.3%, with an adjusted housing gross profit margin of 15.5%, which is 480 basis points lower than the previous year due to pricing pressure and higher land costs [31][34]. - The company returned almost $70 million in capital to shareholders in the first quarter, including share repurchases and dividends [8][40]. Business Line Data and Key Metrics Changes - The company delivered 2,370 homes in the first quarter, which was below the level needed to maintain prior full-year delivery guidance [29][12]. - The average selling price (ASP) declined by 10% to $452,000 due to regional and product mix and general market conditions [30]. - Built to Order (BTO) homes represented 44% of net orders in October, increasing to 68% by February and above 70% in early March, which typically generates higher gross margins [14][12]. Market Data and Key Metrics Changes - The company ended the first quarter with 276 active communities, an 8% increase year-over-year, and achieved 37 grand openings in the first quarter [20]. - The company noted that consumer confidence remains tepid due to elevated mortgage interest rates and affordability pressures, which have stifled underlying demand [11][12]. - The conflict in the Middle East has added uncertainty to the market, impacting consumer sentiment and sales [8][49]. Company Strategy and Development Direction - The company is refocusing on its core Built to Order strategy, which is expected to strengthen the business and improve predictability in deliveries and gross margins [5][17]. - The company plans to continue its share repurchase program in fiscal 2026, with between $50 million and $100 million of repurchases planned for the second quarter [27][40]. - The growth strategy remains centered on expanding market share within existing markets, with a focus on long-term economic and demographic growth [26]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term housing market, citing favorable demographics and structural undersupply of homes, despite current market challenges [11][12]. - The company anticipates a turning point in the second quarter, expecting to grow its backlog relative to the prior year period and drive sequential increases in deliveries [16][12]. - Management acknowledged the uncertainty in the market due to geopolitical tensions and affordability concerns, which led to a reduction in full-year guidance [8][49]. Other Important Information - The company has a favorable lot position, owning or controlling over 63,000 lots, with a disciplined approach to land investments [26][37]. - The average cash down payment for buyers was 16%, with a household income of approximately $133,000 and a FICO score of 743 [23]. - The company has implemented a 10% year-over-year headcount reduction to align overhead with delivery volume [25]. Q&A Session Summary Question: What does the shift to Built to Order do for the business? - Management indicated that the shift to Built to Order enhances predictability and allows for better cash management, as homes are sold before construction begins, improving operational efficiency [42][66]. Question: What drove the guidance change? - The guidance change was attributed to lower-than-expected orders and recent market shifts, including geopolitical tensions affecting consumer confidence [46][49]. Question: What is the outlook for gross margins? - Management expects gross margins to improve in the second half of the year due to a higher mix of Built to Order homes and favorable regional contributions [75][76]. Question: How are pricing trends in communities? - Approximately 70% of communities experienced stable or increasing prices, while 30% saw price reductions as the company optimizes its assets [80]. Question: What is the risk of higher rates on backlog? - Management noted that while higher rates could impact buyer qualification, the current buyer profile remains strong, with many creating personal value in their homes [82][69].

Financial Data and Key Metrics Changes - For the full year 2025, revenue increased by 40.5% to $82 million, net income rose by 98% to $7.6 million, and adjusted EBITDA increased by 107% to $19.9 million [3][4] - Operating margins improved by 723 basis points, indicating a significant inflection point for future revenue growth and profitability [4][18] Business Line Data and Key Metrics Changes - The Patient Affordability business saw annual revenue growth of 168%, reaching $33.9 million compared to $12.7 million in 2024, with claims processed increasing by approximately 79% [4][16] - Plasma donor compensation revenue increased by 4% to $45.6 million, driven by the addition of 115 net plasma centers, despite a decline in average plasma donations per center [13][17] Market Data and Key Metrics Changes - The company has active programs with six of the top 10 U.S. pharmaceutical manufacturers ranked by revenue, indicating strong market penetration [6] - The Patient Affordability platform helped deliver nearly $1 billion in financial assistance to over 840,000 individuals in 2025 [4] Company Strategy and Development Direction - The company aims to continue scaling its Patient Affordability business, which has become a central driver of growth and profitability, while also maintaining a stable plasma business [14][15] - The focus remains on enhancing the dynamic business rules technology to provide better economic value for pharmaceutical manufacturers [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Patient Affordability business, expecting continued momentum into 2026 with revenue guidance of $106.5 million to $110.5 million [21][22] - The company does not foresee significant threats from legislative changes or competition, viewing current dynamics as reinforcing the need for their solutions [11][24] Other Important Information - The company exited 2025 with $21.1 million in cash, nearly double from the prior year, and has zero bank debt [20] - The outlook for 2026 includes expectations for gross profit margins between 60%-62% and operating expenses to increase by 20% [22][23] Q&A Session Summary Question: Observations on pharma manufacturers' recent activity - Management noted no slowdown in activity among pharma manufacturers, citing strong pipelines and ongoing investments in innovation [26][27] Question: GLP-1 products on the platform - Currently, the company does not have major GLP-1 products but is actively pursuing opportunities in that market [29][30] Question: Insights on fixed costs and operating leverage - Management indicated that fixed costs are expected to plateau, with a focus on controlling SG&A growth to enhance operating leverage [32][33] Question: Pipeline for patient affordability programs - Management refrained from providing specific guidance on the pipeline at this early stage but indicated that evaluations would occur after key industry conferences [75][79] Question: Investor understanding of the business model - Management acknowledged that there is a need to better communicate the co-pay model and the unique advantages of their offerings to investors [80][86]

Financial Data and Key Metrics Changes - Total revenues for the first quarter of fiscal 2026 were approximately $1.1 billion, with diluted earnings per share at $0.52, reflecting a 23% year-over-year decrease in housing revenues [5][28]. - Housing gross profit margin was reported at 15.3%, with an adjusted housing gross profit margin of 15.5%, down 480 basis points year-over-year due to pricing pressure and higher land costs [29][30]. - The company returned almost $70 million in capital to shareholders in the first quarter, including share repurchases and dividends [6][38]. Business Line Data and Key Metrics Changes - The company delivered 2,370 homes in the first quarter, which was near the midpoint of guidance but below expectations needed to maintain prior full-year delivery guidance [28][30]. - The average selling price (ASP) declined by 10% to $452,000, influenced by regional and product mix [29]. - Built to Order (BTO) homes represented 44% of net orders in October, increasing to 68% by February and above 70% in early March, which typically generates higher gross margins [12][13]. Market Data and Key Metrics Changes - The company ended the first quarter with 276 active communities, an 8% increase year-over-year, and achieved 37 grand openings [19]. - The company noted that consumer confidence remains tepid due to elevated mortgage rates and affordability pressures, compounded by geopolitical tensions [10][11]. - The company anticipates a more favorable regional mix in the second half of the year, particularly from Northern California, which has historically higher ASPs and margins [16][17]. Company Strategy and Development Direction - The company is refocusing on its core Built to Order strategy, which is expected to enhance predictability in deliveries and improve gross margins [4][12]. - The company plans to continue its share repurchase program, with $50 million to $100 million of repurchases planned for the second quarter [26][38]. - The long-term strategy includes managing capital effectively while expanding market share in existing markets, with a focus on land investments to support growth [25][36]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term housing market, citing favorable demographics and structural undersupply of homes, despite current market challenges [10][11]. - The company is lowering its full-year delivery guidance due to lower net orders in the first quarter and ongoing market uncertainties [6][30]. - Management highlighted the importance of operational execution and adherence to the Built to Order model to navigate market conditions effectively [22][26]. Other Important Information - The company has a favorable lot position, owning or controlling over 63,000 lots, with a balanced production of homes in process [25][36]. - The company has taken steps to reduce costs, including a 10% year-over-year headcount reduction, which is expected to positively impact the SG&A ratio in the second half of 2026 [23][30]. - The company maintains a strong balance sheet with total liquidity of $1.2 billion and no debt maturities until June 2027 [37][38]. Q&A Session Summary Question: What does the shift back to Built to Order do for the business? - Management indicated that the shift to Built to Order enhances predictability and allows for better cash management, as homes sold not started provide a consistent production cadence [41][43]. Question: What drove the guidance change for the year? - The guidance change was attributed to lower than expected orders and recent market shifts, including geopolitical tensions affecting consumer confidence [45][47]. Question: What is the outlook for gross margins in the second quarter? - Management expects gross margins to be under pressure in the second quarter but anticipates improvements in the second half due to a higher mix of Built to Order homes and favorable regional dynamics [49][53]. Question: How is the company managing pricing in the current market? - The company reported that about 70% of communities had stable or increasing prices, while 30% experienced price reductions to optimize sales [80]. Question: How is the company addressing potential risks from rising mortgage rates? - Management is evaluating customer deposits and may adjust them based on market conditions, emphasizing the value created through the personalized home buying process [68][70].

Financial Data and Key Metrics Changes - For the full year 2025, revenue increased by 40.5% to $82 million, net income rose by 98% to $7.6 million, and adjusted EBITDA increased by 107% to $19.9 million [3][4] - Operating margins improved by 723 basis points, indicating a significant inflection point for future revenue growth and profitability [4][20] Business Line Data and Key Metrics Changes - The patient affordability business saw annual revenue growth of 168%, reaching $33.9 million compared to $12.7 million in 2024, with claims processed increasing by approximately 79% [4][18] - Plasma donor compensation revenue increased by 4% to $45.6 million, driven by the addition of 115 net plasma centers, despite a decline in average plasma donations per center [14][19] Market Data and Key Metrics Changes - The company has active programs with six of the top 10 U.S. pharmaceutical manufacturers ranked by revenue, indicating strong market penetration [6] - The patient affordability platform delivered nearly $1 billion in financial assistance to patients, supporting access to high-cost therapies for over 840,000 individuals [4] Company Strategy and Development Direction - The company aims to continue scaling its patient affordability business, which has become a central driver of growth and profitability, while also maintaining a stable foundation through its plasma business [16][24] - The company is focused on enhancing its dynamic business rules technology to help pharmaceutical manufacturers manage co-pay assistance more effectively [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy and highlighted the continued demand for solutions that improve patient access while driving economic value for manufacturers [9][12] - The outlook for 2026 anticipates revenue growth of 30%-35%, with plasma and pharma contributing equally, and gross profit margins expected to be between 60%-62% [22][24] Other Important Information - The company exited 2025 with $21.1 million in cash, almost double from the prior year, and continues to have zero bank debt [21] - The company is actively working on integrating its donor management system with plasmapheresis devices and expects positive feedback from blood and plasma collection organizations [16] Q&A Session Summary Question: Observations on pharma manufacturers' recent activity - Management noted that there is no slowdown in activity among pharma manufacturers, with strong pipelines and ongoing investments in innovation [29][30] Question: GLP-1 products on the platform - The company does not currently have major GLP-1 products but is making efforts to penetrate that market, particularly for diabetes-related products [32][33] Question: Insights on fixed costs and operating leverage - Management indicated that fixed costs are expected to plateau, with a significant reduction in incremental costs as the business grows, allowing for improved operating leverage [35][36] Question: Pipeline for patient affordability programs - Management stated that they do not provide guidance on the pipeline this early in the year but will evaluate it further after key industry conferences [79][83] Question: Investor concerns regarding AI and competitive advantages - Management reassured that AI is not viewed as a threat but rather as a tool to enhance their offerings, emphasizing their unique dynamic business rules technology [94][95]

Financial Data and Key Metrics Changes - Research and development revenue for Q4 2025 was $3.8 million, down from $7.6 million in Q4 2024, reflecting a reduction in reimbursed study costs as the company neared completion of the base phase under the BARDA contract [17] - Gross margin for Q4 2025 was 39.8%, compared to 44.0% in Q4 2024, primarily due to a lower percentage of reimbursed direct labor [17] - Net income for Q4 2025 was $0.6 million or $0.02 per diluted share, compared to a net loss of $7.7 million or -$0.41 per diluted share in Q4 2024 [18] - For the full year, research and development revenue decreased to $19.7 million from $29.6 million, while gross margin remained stable at 45.4% compared to 44.9% [19] - The net loss for the year was $7.6 million or $(0.29) per diluted share, improved from a net loss of $15.3 million or $(0.85) per diluted share in the previous year [20] - Cash position improved to $15.4 million from $5.2 million at the end of 2024, reflecting financing activities and exercises of warrants and stock options [20] Business Line Data and Key Metrics Changes - The DeepView system is positioned as a diagnostic tool for burn injuries, with significant advancements made in 2025, including a pivotal FDA submission [6][9] - The company completed a major burn validation study involving 164 patients, which demonstrated the DeepView system's superiority over clinical judgment [7] - BARDA reaffirmed its commitment by awarding $31.7 million in advanced funding to support the DeepView system's development [10] Market Data and Key Metrics Changes - Approximately 125 burn centers, 700 trauma centers, and 5,400 hospitals in the U.S. represent potential markets for the DeepView system [9] - Internationally, positive user feedback has been received from the DeepView systems placed in the UK, with plans for initial sales in the UK, Australia, and GCC nations anticipated in late 2026 [12] Company Strategy and Development Direction - The company aims to commercialize the DeepView system, focusing on rapid market adoption and expanding its sales team in preparation for FDA approval [12][25] - Plans include enhancing the DeepView system's features, such as total body surface area measurement and electronic health record integration [11][30] - The company is also exploring label expansions and additional indications for the DeepView system beyond burn injuries [56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about receiving FDA approval for the DeepView system by the end of Q2 2026, which would enable commercial activities to commence [7] - The company entered 2026 with a strong liquidity position, allowing it to pursue growth objectives effectively [15] - Revenue guidance for 2026 is approximately $18.5 million, reflecting the impact of new BARDA funding [21] Other Important Information - The company is working with Deloitte Consulting to develop a strategic plan for commercialization [25] - A no-cost extension of the Department of Defense contract was signed to continue developing a handheld device through June 2026 [13] Q&A Session Summary Question: Preparation for commercialization - The company is searching for a new Chief Commercial Officer and expanding its sales team to prepare for commercialization [25] Question: Impact of BARDA's distribution of systems - Each health system will determine how to treat the device, impacting revenue recognition, with potential for significant revenue in 2027 and 2028 [27] Question: Use of additional BARDA funding - The funding will support label expansion, improvements to the DeepView system, and enhanced user experience [30] Question: Timeline for BARDA funds disbursement - The BARDA contract extends until 2030, with an acceleration of revenue expected through 2028 [43] Question: Training for device implementation - The company plans to expand its training force to ensure effective implementation and usage of the DeepView system [51] Question: R&D spend allocation - The company will focus on label expansion and exploring additional indications for the DeepView system [56]

Financial Data and Key Metrics Changes - Total sales grew by 25% year-over-year to $845 million, with 14% organic adjusted sales growth [12][4] - Adjusted operating income increased by 31% to $86.2 million, and adjusted EBITDA rose by 26% to $102.1 million [12][13] - Adjusted diluted EPS was up 26% year-over-year to $1.25 per share [13] Business Line Data and Key Metrics Changes - Parts supply sales grew by 45% to $392.5 million, with new parts distribution growing 62% in total and 36% organically [14] - Repair and engineering sales increased by 23% to $265 million, though margins were negatively impacted due to the integration of HAECO Americas [15][16] - Integrated solutions sales rose by 3% to $167.8 million, driven by Trax and government programs [18] Market Data and Key Metrics Changes - Sales to commercial customers were up 27%, while sales to government customers increased by 19% [12] - Government customers accounted for approximately 30% of total sales, with a 19% increase in government sales this quarter [9][12] Company Strategy and Development Direction - The company is focused on strategic priorities, including the integration of HAECO Americas and expansion of hangar operations [5] - AAR is positioned as an independent value-added aftermarket solution provider, benefiting from a balanced exposure to both government and commercial markets [8] - The company plans to host an investor day to share its strategic vision and growth plans [21] Management's Comments on Operating Environment and Future Outlook - Management noted strong fundamental demand for air travel, with record bookings despite geopolitical tensions [6][29] - The company expects total adjusted sales growth of 19%-21% for Q4, with organic adjusted sales growth projected between 6% and 8% [20] - Management expressed confidence in maintaining strong operational performance and cash flow generation [48] Other Important Information - The company ended the third quarter with net leverage at 2.17 times net debt to adjusted EBITDA, within the target range [19] - The integration of HAECO Americas is progressing ahead of schedule, with expectations for margin improvement in the future [13][75] Q&A Session Summary Question: Impact of oil prices and capacity adjustments on business - Management indicated that fundamental demand for air travel remains strong, and modest capacity adjustments are not expected to impact maintenance schedules or parts demand [27][28] Question: Breakdown of organic growth in new parts distribution - Approximately two-thirds of the growth in new parts distribution was from same-store sales, with the remaining third from new contract wins [30][31] Question: Visibility on new parts distribution and repair and engineering - Management expressed solid visibility through the quarter and into the summer, with no material changes in demand for maintenance or component repair [39][40] Question: Sources of outperformance in margins - Key contributors to margin outperformance included the performance of ADI and strong results from Trax [41] Question: Integration progress of HAECO Americas - Integration is ahead of schedule, with significant changes made to align the workforce with the new revenue base [72][73]

Financial Data and Key Metrics Changes - Total expenses increased approximately 3% year-over-year to $8.3 million in 2025, compared to $8.1 million in 2024 [15] - Research and development expenses rose to $5 million in 2025 from $4.4 million in 2024, a 13% increase primarily due to trial activities and regulatory efforts [15] - Selling, general and administrative expenses decreased 10% to $3.3 million in 2025 from $3.7 million in 2024 [16] - Net loss increased modestly to $8.2 million in 2025 from $7.9 million in 2024 [16] - Cash and cash equivalents totaled $2.5 million at the end of 2025, comparable to $2.4 million at the end of 2024 [16] Business Line Data and Key Metrics Changes - The lead program remains the CardiAMP cell therapy targeting ischemic heart failure, with significant clinical trial data supporting its efficacy [4][5] - The CardiAMP HF trial showed reductions in left ventricular volume with p-values approaching significance, particularly in subgroups with elevated biomarkers of heart stress [6][28] Market Data and Key Metrics Changes - The U.S. market for ischemic heart failure includes approximately 1 million patients, with Japan having around 150,000 patients [4] - Recent developments in Japan include conditional approval for another allogeneic cell therapy for ischemic heart failure, indicating a competitive landscape [10] Company Strategy and Development Direction - The company aims to advance its CardiAMP and CardiALLO therapies while seeking regulatory approvals in the U.S. and Japan [12][14] - The strategy includes engaging with regulatory bodies for potential near-term approvals and completing the CardiAMP HF II confirmatory clinical study [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical data supporting CardiAMP therapy and its potential to address significant unmet needs in heart failure [7][29] - The company anticipates a consistent cash burn in 2026 while managing resources carefully [16] Other Important Information - The company has four upcoming catalysts, including FDA submissions and clinical consultations with Japan's PMDA [12][13] - The CardiAMP HF II trial is designed to focus on the most responsive patient subgroups, leveraging learnings from previous trials [11] Q&A Session Summary Question: Can you provide insights on the echo data presented at THT? - Management noted that while p-values for the complete population were not statistically significant, they were approaching significance, particularly in subgroups with elevated NT-proBNP [25][26] Question: What is the timeline for the CardiAMP submission to the FDA? - The company expects to file for a discussion on approvable pathways imminently, with a potential 45-day turnaround for feedback from the FDA [30] Question: How is enrollment in the HF II trial progressing? - Enrollment is starting slowly due to resource allocation towards regulatory submissions, but interest from clinical sites is strong [53] Question: How does CardiAMP HF compete with other cell therapies? - Management believes CardiAMP will remain a leading therapy due to its straightforward and cost-effective nature, despite the competitive landscape [41][43]

Financial Data and Key Metrics Changes - Revenue for the fourth quarter was $700,000, with research and development expenses increasing to $25.3 million from $18.4 million year-over-year, primarily due to advancements in internal programs [26][27] - Selling, general, and administrative expenses were $8.6 million, slightly down from $8.8 million in the prior year [26] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $144.3 million, down from $152.5 million as of September 30, 2025, indicating a strong cash position to fund operations into the first half of 2028 [27][28] Business Line Data and Key Metrics Changes - The company is advancing its lead program, ABS-201, for androgenetic alopecia (AGA) and endometriosis, with a focus on clinical development and potential market opportunities [20][29] - ABS-201 is currently in a phase I/IIa HEADLINE trial, with favorable emerging safety data reported from the first three cohorts dosed [19][29] Market Data and Key Metrics Changes - The total addressable market for ABS-201 in the U.S. for AGA is estimated at approximately $25 billion annually, with a potential patient population of 15-18 million consumers [23] - Endometriosis is estimated to affect about 10% of women of reproductive age worldwide, representing a significant market opportunity with no FDA-approved disease-modifying therapy currently available [12][29] Company Strategy and Development Direction - The company aims to target underexplored areas in large markets with significant unmet needs and low competition, focusing resources on ABS-201 while engaging in discussions for partnerships on other programs [13][14] - The strategy includes leveraging the generative AI platform, Origin-1, for efficient drug design and development, which has shown to reduce time and costs compared to industry standards [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical momentum and the ability to reach proof of concept for both AGA and endometriosis, with key data readouts expected in 2026 and 2027 [29] - The company is optimistic about the potential for ABS-201 to provide durable hair regrowth and address significant unmet medical needs in both indications [20][29] Other Important Information - The company has expanded its advisory networks for both AGA and endometriosis, enhancing its clinical trial design and endpoint selection [9][12] - The company recorded a $5.1 million gain on the settlement of contingent consideration during the fourth quarter of 2025, contributing to its cash position [27] Q&A Session Summary Question: What should investors look for in terms of ABS-201's target product profile? - Management aims for ABS-201 to achieve durable treatment and efficacy at or above minoxidil levels, with a target of 35-40 hairs per square centimeter [31][34] Question: Can you elaborate on the safety profile observed in the SAD portion of the trial? - Early data shows no evidence of on-target or off-target safety signals, which is encouraging [39][40] Question: How do you envision ABS-201's market opportunity compared to other agents in development? - Management sees ABS-201 as synergistic with existing treatments, offering a novel mechanism and potentially more convenient dosing [68][70] Question: What are the expected challenges in developing a drug for endometriosis? - Pain studies require careful site selection and protocol design to mitigate placebo effects, which is critical for assessing treatment efficacy [84] Question: How should resource allocation be viewed between AGA and endometriosis? - Both opportunities are significant, with a streamlined development path allowing for efficient resource allocation [85][86]